HPV vaccine: Cervarix (Q37687426)

22 August 2017

1 reference

title

HPV vaccine: Cervarix (English)

1 reference

22 August 2017

1 reference

1 reference

1

Anne Szarewski

1 reference

PubMed ID

20132062

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

3

1 reference

22 August 2017

477-487

1 reference

The cervical cancer epidemic that screening has prevented in the UK.

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Psychological costs of inadequate cervical smear test results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

PUBLIC HEALTH: High Hopes and Dilemmas for a Cervical Cancer Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Adverse psychologic consequences of positive cytologic cervical screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Epidemiology of Genital Human Papillomavirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Immune responses to human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Clinician's guide to human papillomavirus immunology: knowns and unknowns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Booster vaccinations: can immunologic memory outpace disease pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Cervical human papillomavirus screening among older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Three provinces to study 2-dose HPV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

HPV vaccines: peering through the fog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Mathematical model of HPV provides insight into impacts of risk factors and vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Anal intraepithelial neoplasia in HIV positive people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Chapter 17: Second generation HPV vaccines to prevent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

HPV and cervical cancer: screening or vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003601944

10.1517/14712591003601944

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20132062